17-05-2025
Maxim Group Sticks to Its Buy Rating for MetaVia (MTVA)
Maxim Group analyst Jason McCarthy maintained a Buy rating on MetaVia (MTVA – Research Report) yesterday. The company's shares closed yesterday at $0.68.
Confident Investing Starts Here:
Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group, Actinium Pharmaceuticals, and Gain Therapeutics. According to TipRanks, McCarthy has an average return of -21.7% and a 26.41% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for MetaVia with a $9.00 average price target.
